Market Place
Sourcing Support
iOnctura reaches new clinical milestones in uveal melanoma
11 Dec 2024 //
PR NEWSWIRE
iOnctura announces expansion of roginolisib clinical trial program to NSCLC
09 Jul 2024 //
PR NEWSWIRE
IOnctura Raises EUR80M Series B To Advance Pipeline Through Phase II Trials
20 Jun 2024 //
PR NEWSWIRE
US FDA grants Orphan Drug Designation for iOnctura`s autotaxin cancer therapy
07 Mar 2024 //
PR NEWSWIRE
Updated clinical safety and efficacy data for iOnctura`s roginolisib presented
08 Dec 2023 //
PR NEWSWIRE
iOnctura to present research on roginolisib and IOA-359 at ASH
03 Nov 2023 //
PR NEWSWIRE
iOnctura announces FDA clearance of IND application for roginolisib
31 Oct 2023 //
PR NEWSWIRE
New research highlights potential of iOnctura strategy combining autotaxin
19 Oct 2023 //
PR NEWSWIRE
iOnctura to present research at leading scientific conferences in June 2023
01 Jun 2023 //
PR NEWSWIRE
iOnctura exp&s pipeline & receives development grant from Health Holl& & KWF
03 May 2023 //
BUSINESSWIRE
iOnctura and Clavius exercise option for TGF-? pathway inhibitor
03 May 2023 //
PHARMACEUTICAL TECHNOLOGY
iOnctura awarded UK`s MHRA Innovation Passport for entry into ILAP
28 Mar 2023 //
PR NEWSWIRE
iOnctura reveals roginolisib research results
17 Mar 2023 //
PHARMATIMES
iOnctura announces publication of research describing thefeatures of roginolisib
16 Mar 2023 //
PR NEWSWIRE
iOnctura provides development update on first-in-class semi-allosteric PI3K?
05 Jan 2023 //
PR NEWSWIRE
iOnctura awarded EUR17.5 million funding from the EIC Accelerato
20 Dec 2022 //
PR NEWSWIRE
iOnctura initiates Ph Ib pancreatic cancer trial of next-generation IOA-289
08 Dec 2022 //
GLOBENEWSWIRE
iOnctura expands Advisory Board
26 Sep 2022 //
GLOBENEWSWIRE
iOnctura to Present at ASCO IOA-244
26 May 2022 //
BUSINESSWIRE
iOnctura to present at ASCO Phase Ib refractory uveal melanoma data for IOA-244
16 May 2022 //
BUSINESSWIRE
iOnctura Presents Data at AACR on Clinical Stage ATX Inhibitor IOA-289
08 Apr 2022 //
GLOBENEWSWIRE
iOnctura to Present PC Data on IOA-289, at AACR
09 Mar 2022 //
GLOBENEWSWIRE
iOnctura Shows No Dose-limiting Toxicity and Reduced T-regs in Solid Tumor
09 Dec 2021 //
GLOBENEWSWIRE
iOnctura Presents Positive Clinical Data At ESMO-IO Supporting of IOA-289
09 Dec 2021 //
GLOBENEWSWIRE
iOnctura to Share Clinical and Preclinical Data on IOA-244 and IOA-289
23 Nov 2021 //
FIRSTWORDPHARMA
iOnctura Presents Compelling Preclinical Data on IOA-289 at SITC
12 Nov 2021 //
GLOBENEWSWIRE
iOnctura- Dose in Healthy Volunteer for Next Gen Autotaxin Inhibitor IOA-289
20 Jul 2021 //
GLOBENEWSWIRE
First Dose in Healthy Volunteer for Next Generation Autotaxin Inhibitor IOA-289
20 Jul 2021 //
GLOBENEWSWIRE
iOnctura Announces First Patient Dosed in a Ph I Clinical Study
26 Feb 2020 //
PR NEWSWIRE
